Drug Type Synthetic peptide |
Synonyms- |
Target |
Action inhibitors |
Mechanism SARS-CoV-2 3CLpro inhibitors(SARS-CoV-2-3C-like-proteinase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC29H31N5O4S |
InChIKeyJMBJZTHVHMZAKN-NYVOZVTQSA-N |
CAS Registry1471484-52-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Severe Acute Respiratory Syndrome | Preclinical | Japan | 09 Aug 2013 |